Congress Proposes Public-Private Partnership For CIR
This article was originally published in The Rose Sheet
Executive Summary
In reports accompanying draft fiscal 2016 funding bills, both House and Senate committees recommend that FDA work with industry to explore formalizing the Cosmetic Ingredient Review via a public-private partnership similar to that in place with the U.S. Pharmacopeial Convention.